2025年前三季度,A股497家药企中净利润排名前十的企业依次为药明康德、迈瑞医疗、恒瑞医药、新和成、上海医药等。药明康德以120.76亿元的归母净利润位居榜首,同比增长84.84%,主要得益于CRDMO业务模式的持续聚焦及优化,以及出售联营企业部分股票的收益。迈瑞医疗归母净利润达75.70亿元,三大核心业务稳健发展,尤其体外诊断业务表现突出。恒瑞医药归母净利润为57.51亿元,通过创新药研发和...
Source Link2025年前三季度,A股497家药企中净利润排名前十的企业依次为药明康德、迈瑞医疗、恒瑞医药、新和成、上海医药等。药明康德以120.76亿元的归母净利润位居榜首,同比增长84.84%,主要得益于CRDMO业务模式的持续聚焦及优化,以及出售联营企业部分股票的收益。迈瑞医疗归母净利润达75.70亿元,三大核心业务稳健发展,尤其体外诊断业务表现突出。恒瑞医药归母净利润为57.51亿元,通过创新药研发和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.